Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study have?
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study has 416 citations in the OpenAlex counts ScholarIQ stores.
When was Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study published?
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study has 2020 year in the ScholarIQ index.
What is the open-access status of Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study?
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study has bronze oa status in the ScholarIQ index.
What is the DOI of Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study?
The DOI for Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study is on the source record.
What is the PMID of Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study?
The PMID for Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study is on the source record.
What is the OpenAlex record for Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study?
The OpenAlex for Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study is on the source record.